glaxosmithkline manufacturer lamotrigine lamictal antiepileptic drug used widely bipolar disorder happily hid clinical trial results found lamictal better placebo given recent findings often pharmaceutical companies selectively push positive results publication medical journals suppressing negative results hardly considered surprise nonetheless instructive examine published data lamictal paint much rosier picture drug efficacy compared unpublished data nassir ghaemi psychiatrist tufts university medical center dug gsk online database information found several negative lamictal studies studies failed show benefit lamictal placebo primary outcome measure quietly residing site gsk post information site goodness hearts rather forced post data clinical trial outcomes result legal agreement ghaemi found gsk database acute mania two studies compared lithium lamictal placebo found lamictal beat placebo neither study published acute bipolar depression three studies conducted three showed negative results two published one study positive result lamictal secondary outcome measure results study written emphasize positive outcomes stating lamotrigine monotherapy effective well tolerated treatment bipolar depression rapid cycling bipolar two studies completed negative primary outcome however one study showed favorable outcomes lamictal several secondary measures obviously negative study published study showed number benefits lamictal published prophylaxis prevention future episodes two studies conducted showed patients lamictal went longer episodes placebo patients studies published well i shocked shocked gsk would simply bury slew negative data product woulda thunk mean lamictal dr ghaemi interviewed dr daniel carlat carlat psychiatry blog carlat psychiatry report many pieces ghaemi interview interesting see february issue carlat psychiatry report sorry link available interesting piece carlat understanding wrote discovery negative lamictal data submitted paper journals response ghaemi i first submitted jama i knews sympathetic kind critique reaction already publish many papers like old news nothing new recommended i send psychiatric journal i sent american journal psychiatry rejected well saying doubtful type negative publication bias common among companies marketing medications bipolar disorder carlat think much suppressed negative data drugs ghaemi hard get information companies required disclose publish sometimes delay publication two three years publish obscure journal less likely read ghaemi also digging drugs used bipolar disorder found negative studies seroquel abilify also lurking unpublished zone however appears lamictal worst offender bunch me anyone else getting flashbacks gsk handling suicide data regarding antidepressant paxil thanks anonymous reader helping track relevant information upcoming post topic forthcoming post deal misleading scientific literature lamictal key opinion leaders likely mentioned usual stuff different drug plugging names academics apparently deemed acceptable mislead fellow physicians efficacy lamotrigine gsk worked system expertly paid nassir ghaemi arshia shitzadi megan filkowski publication bias pharmaceutical industry case lamotrigine bipolar disorder medscape journal medicine